China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products in the People's Republic of China and internationally. It also provides related health services. The company offers OTC products, including cold, skin, gastrointestinal, cough relieving, orthopedics, and pediatrics drugs; prescription drug products in traditional Chinese medicine, tumors, cardiovascular and cerebrovascular, digestive system, orthopedics, and pediatrics; Chinese medicine injections; formula granules; and anti-infective drugs. It sells its products under 999 family medicine brands, Sanjiuweitai series, 999 Ganmaoling series, 999 dermatitis series, and other products. The company was formerly known as Sanjiu Pharmaceutical Co., Ltd. and changed its name to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. in February 2010. The company was founded in 1999 and is based in Shenzhen, the People's Republic of China. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a subsidiary of China Resources (Holdings) Co., Ltd.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

CanSino Biologics Inc.

华润三九医药股份有限公司 is involved in the pharmaceutical industry, focusing on traditional Chinese medicine and related health products.

Metric
Company Name	China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.	CanSino Biologics Inc.
Symbol	999	6.18K
MSH ID	CN:COM:999	COM:CANSINOTECH
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Drug Manufacturers - Specialty & Generic	Drug Manufacturers - Specialty & Generic
Country	CN	CN
Stage
Employee Count	20.32K	1.49K
Website	999.com.cn	cansinotech.com
LinkedIn		cansino-biotechnology-inc.
Founders

Metric
Market Cap	7.27B	833.96M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	3.36B	49.12M
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.73B	-61.04M
EBITDA	602.14M	-203.86M
Operating Income	484.72M	-236.92M
Net Income	392.41M	-203.94M
EPS	0.40	-0.83
Diluted EPS	0.40	-0.83
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.53	0.14
Operating Profit Margin	0.16	-0.86
EBITDA Margin	0.18	-4.15
Net Profit Margin	0.13	-1.42
Return on Equity	0.17	-0.16
Return on Assets	0.08	-0.11
Return on Capital Employed	0.15	-0.08

0009

CN:COM:999

华润三九医药股份有限公司

Last Close

45.69

25/11 07:04

Market Cap

52.85B

Beta: -

Volume Today

9.99M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	19.26
P/B Ratio	3.02
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.60	20.35
EV Multiple	15.32	-3.00

Metric
Days Sales Outstanding	127.05	485.87
Days Payables Outstanding	92.05	170.20
Days Inventory Outstanding	151.91	251.49
Operating Cycle	278.23	815.83
Cash Conversion Cycle	205.87	770.86
Asset Turnover	0.64	0.07

Metric
Operating Cash Flow	580.50M	-124.92M
Free Cash Flow	462.59M	-208.89M
Cash Flow to Debt	1.51	-0.12
Operating Cash Flow/Sales	0.19	-0.43
Free Cash Flow Yield	0.06	-0.25

Metric
Cash & Equivalents	873.89M	388.10M
Accounts Receivable	87.16M	36.58M
Inventory	703.20M	48.53M
Goodwill	704.78M
Debt to Capitalization	0.16	0.34
Debt to Assets	0.08	0.21
Current Ratio	1.77	2.24
Quick Ratio	1.48	2.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.03	1.04
SG&A to Revenue	0.03	0.34